X
Search
X

Patient Support Hotline

Call (844) 244-1309

ZERO360 is a free, comprehensive patient support service to help patients and their families navigate insurance and financial obstacles to cover treatment and other critical needs associated with cancer.

X

Subscribe to our E-Newsletter

Stay up-to-date on the latest news about prostate cancer. Join our distribution list to receive periodic email updates and our monthly e-newsletter.

  • Patient Support (844) 244-1309
  • Search
  • e-News Signup Enews Signup
  • Run/Walk
  • Donate

FDA Approval Sought for Abiraterone Acetate for Early-Stage Metastatic Prostate Cancer

A supplemental new drug application has been submitted for abiraterone acetate (Zytiga) in combination with prednisone and androgen deprivation therapy (ADT) for high-risk patients with metastatic hormone-naïve prostate cancer (HNPC) or newly-diagnosed metastatic hormone-sensitive prostate cancer (HSPC), according to a statement from the company developing therapy, Janssen Biotech.

Read more.

source: OncLive